Human polymorphonuclear leukocytes (PMN) activated by n-formyl-methionyl-leucyl-phenylalanine (fMLP), in the presence of cytochalasin B, are able to induce activation of coincubated autologous platelets "via" cathepsin G released from the azurophilic granules. However, thromboxane (Tx) B2 production in this system cannot be completely explained by cathepsin G-stimulated platelet arachidonate metabolism. Indeed, the amount of TxB2found in supernatants of platelet/ PMN suspensions challenged with 1 pmol/L fMLP was twofold to fourfold higher than that measured when platelets were stimulated by supernatants from fMLP-activated PMN. In the present report, we analyzed the possibility that PMN-induced TxB2 production in this system is the result of transcellular metabolism of arachidonic acid (AA) between fMLP-activated PMN and cathepsin G-stimulated platelets.
H interact with platelets in several settings, including hemostasis, inflammation, and a variety of vascular disorders. ' In a previous report: we showed that PMN activated by n-formyl-methionyl-leucyl-phenylalanine (fMLP) are able to induce aggregation, cytoplasmic calcium increase, and thromboxane (Tx) Bz production in coincubated autologous platelets. In this system, platelet activation was mainly due to cathepsin G released in extracellular medium from the azurophilic granules of activated PMN.2,3 Cell-free supematants from fMLP-activated PMN also stimulated the above mentioned platelet responses. However, T& production was three times lower than that observed when platelets were activated by PMN in mixed cell suspensions.
Because the release of enzymes from the azurophilic granules of PMN was similar in the presence or absence of platelets after 1 p,mol/L fMLP activation of PMN, the possibility was excluded that increased TxBz production was due to a greater availability of the agonist. The possibility that other short-lived agonists, such as oxygen radicals, potentiating cathepsin G-induced platelet activation in mixed cells suspensions could also be excluded. 2 The suggestion was made that TxBz production during platelet-PMN contact in this system could result not only from platelet arachidonate metabolism activation induced by cathepsin G, but also from transcellular cooperation in arachidonic acid (AA) metabolism. In the past few years, cooperation between cells in the processing of reactive precursors and intermediates of AA metabolism into biologically active compounds has emerged as an important concept !- 6 The aim of this study was to investigate the possibility that the greater production of TxBz observed when platelets and PMN are activated together forming mixed aggregates could be the result of a transfer of AA (or a metabolite) from PMN to platelets.
MATERIALS AND METHODS
WLP, prostaglandin (PG) El, PGEz, TxBz, leukotriene (LT) B4,12-hydroxy-eicosatetraenoic acid (HETE), cytocha-
Chemicals.
3H-AA-labeled PMN were used to test if a transfer of AA or metabolite(s) occur from PMN to platelets. Our results showed that: (1) 3H-TxB2 and 3H-12-HHT are synthesized when 3H-AA-labeled PMN are activated mixed to unlabeled platelets; (2) total radioactivity released by fMLP-stimulated PMN is increased in the presence of platelets, whereas the membrane content of unesterified 3H-AA is reduced; (3) platelet cyclooxygenase inhibition completely prevents 3H-TxB2 synthesis; and (4) inhibition of cathepsin G-induced platelet activation with the antiprotease eglin C blocks the formation of 3H-TxB2. These data show that in the experimental system used, platelets use PMN-derived unmetabolized AA to synthesize TxB2. . Dextran T 500 and Ficoll Hypaque were obtained from Pharmacia Fine Chemicals (Uppsala, Sweden); Triton X-100 was obtained from Aldrich Chimica S.r.1. (Milano, Italy); purified human fibrinogen was from Kabi Diagnostica (Stockholm, Sweden); eglin C (recombinant CGP 32968) was kindly provided by Ciba Geigy (Basel, Switzerland); 3H-PGEz, and 3H-T~B2, [5, 6, 8, 9 ,11,12,14,15-"H (N)]-arachidonic acid (3H-AA), specific activity 180 to 240 Cilmmol, were from Du Pont de Nemours (Firenze, Italy); thin-layer chromatography (TLC)-plastic sheets silica gel 60 were from Merck (Darmstadt, Germany). WLP and cytochalasin B were dissolved in dimethyl sulfoxide (DMSO) at concentrations of 50 mmol/L and 100 mmol/L, respectively, stored at -2O"C, and diluted in isotonic saline just before use. Eglin C was dissolved in saline solution.
PMN and platelets were isolated from citrated human blood and washed as described? Aspirin-treated platelets were obtained by incubating platelet-rich Platelets (108/mL), PMN (0.5 X lo7/ mL, except for the dose-response experiments), or a mixture of the two cells were incubated in a final volume of 1 mL of HEPES Tyrode (pH 7.4) in the presence of 1 mmol/L Ca2+, 0.38 mg/mL fibrinogen, and 2.5 wg/mL cytochalasin B in the aggregometer for 2 minutes at 37°C under constant stirring at 1, OOO rpm. Where indicated, eglin C (1 mg/mL) was incubated with the cells 2 minutes before addition of the stimulus. fMLP (1 Fmol/L) was added to the cell suspension and the reaction stopped after 3 minutes; samples were then cooled to 0°C for 15 minutes and centrifuged in an Eppendorf centrifuge, and supernatants were collected, and stored at -20°C until assayed for TxB2. Platelet samples stimulated with PMN supernatants were obtained by addition of 800 pL of supernatants (20-second spin in an Eppendorf centrifuge) from PMN (0.25 to 2 x 107/800 kL) stimulated for 1 minute with fMLP to 108 platelets in a final volume of 1 mL. The production of TxB2 in these samples is reported in Table 1 .
In preliminary experiments, in which fMLP was added to the platelet/PMN mixture (lo8 platelets/0.5 x lo7 PMN/mL) without 2 minutes of prestirring or platelets were added to PMN stimulated for 1 minute with N L P , TxB2 production was reduced to 55% 2 17% and 61% ? 17% (respectively) of TxB2 production in mixed cell suspensions in the standard experimental conditions (mean f SEM, n = 7). All together, these experiments indicated that platelet-PMN contact is important for the observed increase of TxB2 production.
TxB2 was quantitated by radioimmunoassay, using a specific antiserum kindly provided by Prof C. Patron0 (Catholic University, Rome, Italy), as described? The detection limit was 5 pg/mL. TxB2 values are reported as nanograms per milliliter of incubate.
PMN (3 x 107/mL) were incubated (30 minutes at 37°C) with 0.25 pCi/mL of 3H-AA, washed twice, and suspended in Tyrode buffer. 3H-AA incorporation determined was 69% +. 4% (n = 12). Experimental conditions used with 3H-AA-labeled PMN were identical to those used with unlabeled cells.
Aliquots of supernatants from the different samples were immediately counted by liquid scintillation to evaluate the total radioactivity released. To evaluate the release of unesterified 3H-AA in lipophilic membranes of stimulated PMN in the presence or in the absence of platelets, we terminated incubations by adding 3.5 mL of chloroform: methanol (25; After taking aliquots to determine total radioactivity released, supernatants of different samples were acidified to pH 4 with citric acid and lipid-extracted twice with chloroform as described,1° evaporated under nitrogen at 37"C, and stored (-70°C). These samples were analyzed either by TLC or by high performance liquid chromatography (HPLC) as follows. For TLC, dried residues were dissolved in 50 pL of chloroform, spotted on TLC silica gel plates, and developed by using chloroform: methanol: acetic acid:water (908:1. 
Analysis of 3H-TxB~ formation.

HPLC.
RESULTS
TxB2 production was measured in PMN and platelets challenged with fMLP either separately or coincubated. Only when platelets and PMN were coincubated in mixed cell suspensions was TxB2 production measurable (not shown). In these conditions, platelet activation induced by fMLP-activated PMN is essentially mediated by released
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cathepsin G.2 The amount of TxB2 found in supernatants of mixed platelet/PMN suspensions challenged with 1 kmol/L fMLP was twofold to fourfold higher than that measured when platelets were stimulated by supernatants from fMLPactivated PMN (Table 1) . These results suggest that TxB2 production in this system cannot be completely explained by cathepsin G-stimulated platelet arachidonate metabolism.
3H-AA-labeled PMN were used to test if a transfer of AA or metabolite(s) could occur from PMN to platelets. Radioactivity released by PMN stimulated with fMLP was 5.0% f 0.4% (n = 7) of total radioactivity incorporated, and increased to 9.3% f 2.7% (n = 10) in the presence of platelets (P < .05). When platelet/PMN samples were stimulated by fMLP, 15% 2 3% (n = 10) of total radioactivity recovered from TLC migrated with the same Rf of authentic TxB2. In contrast, no detectable 3H-TxB2 was observed when 3H-AA-PMN were activated in the absence of platelets or when platelets were activated by supernatants from fMLP-activated 3H-AA-PMN or when 3H-AA-PMN and platelets were incubated without fMLP ( Table  2 ). In the same samples, no detectable radioactivity cochromatographed with standard 3H-AA (Rf: 0.75).
Because no detectable 3H-AA was present in aqueous supernatants of fMLP-activated PMN alone or in the presence of platelets, the membrane content of unesterified 3H-AA was analyzed in the same experimental conditions. A time-course experiment (Fig 1) shows a maximal release of unesterified 3H-AA at 1 minute after fMLP activation. Measurable unesterified 3H-AA was reduced by the presence of platelets (P < .05 only at 180 seconds). This finding is not in contrast with the increased total radioactivity measured in supernatants of activated platelet/PMN in respect to supernatants of activated PMN alone over reported, because an increased metabolism of PMNderived 3H-AA by platelets or PMN could occur in the presence of platelets. Figure 2 reports the HPLC analysis of radioactive AA metabolism by fMLP-activated PMN in the presence and in the absence of platelets. The most striking difference in the AA metabolites profiles obtained in the presence and in the absence of platelets was constituted by the appearance in the former condition of a large peak eluted with the same retention time of authentic TxB2. No detectable radioactivity was eluted with retention time corresponding to that of lZHETE, while the presence of radioactivity with retention time corresponding to that of IZHHT was detectable only in samples of PMN incubated in the presence of platelets. 3H-TxB2 peak was abolished by aspirin treatment of platelets (Fig 3) , a finding in agreement with T& measurement by radioimmunoassay in comparable nonradioactive samples. Indeed, production of immunoreactive TxBz in platelets/PMN suspensions challenged with fMLP was virtually abolished in samples of aspirin-treated platelets (from 44.2 2 14.4 to 0.6 f 0.3 ng/mL; n = 3). These results indicate that PMN contribute to TXB2 production by providing platelets with unmetabolized AA and suggest an essential role for platelet cyclooxygenase in TxB2 production by mixed cells.
Results (mean
To test if cathepsin G-induced platelet activation is an essential step for transcellular AA metabolism, we performed experiments in the presence of the specific inhibitor of cathepsin G, eglin C.2J1 Eglin C did not affect platelet TxBz production induced by 0.05 to 10 kmol/L AA concentrations (not shown), but completely suppressed 3H-TxB2 production in 3H-AA-PMN-platelet system activated by fMLP (Fig 3) . This finding suggests an essential role for cathepsin G-induced platelet activation in TxB2 synthesis from PMN-derived AA.
DISCUSSION
Human PMN activated with fMLP stimulate Tx& production in coincubated autologous platelets. In these conditions, we observed platelet-leukocyte transcellular metabo- lism in which platelets use AA derived from N L Pactivated PMN to synthesize TxB2.
The background observation was the marked difference in TxB2 production between platelets activated by supernatants from NLP-stimulated PMN and platelets activated by PMN in mixed cell suspensions. In both cases, cathepsin G released by activated PMN was responsible for platelet a~tivation.~.~ When PMN labeled with 3H-AA and unlabeled platelets were stimulated with N L P , 3H-TxB2 was formed. This was evident both with TLC and HPLC. HPLC analysis of 3H-AA metabolites also evidenced radioactive material comigrating with 12-HHT only in fMLP-activated mixed cells samples. The presence in the chromatographic profiles of this metabolite strengthened the finding of platelet cyclooxygenase-dependent metabolism of PMN-derived 3H-AA. No detectable radioactivity was eluted with retention time corresponding to 12-HETJ5 indicating that platelet lipoxygenase is not involved in using PMN-derived 3H-AA in these conditions.
The release of total radioactivity measured in the supernatants of fMLP-activated PMN was significantly higher in the presence of platelets. Because the amount of unesterified 3H-AA was reduced in the presence of platelets, an increased metabolism of PMN-derived AA could explain the higher total radioactivity recovered in supernatants of mixed cell suspension. Our data indicate that platelets provide a new metabolic pathway for PMN-derived AA only through cyclooxygenase metabolism, as indicated by TxB2 and 12-HHT production. On the other hand, previous reports indicate that platelets stimulate metabolization of AA by PMN. 12 The experiments with aspirin-treated platelets clearly indicate that fMLP-activated PMN contribute to TxB2 production in mixed cell suspensions by providing unmetabolized AA to activated platelets.
Moreover, inhibition of cathepsin G-induced platelet activation with the antiprotease eglin C blocked the formation of 3H-TxB2 from PMN-derived 3H-AA. Indeed, platelet activation is required for the formation of mixed platelet/PMN aggregates, in which tight membrane to membrane contact, shown by electron microscopy,2 would favor unesterified AA transfer in a lipophilic environment.
Other pathways of transcellular metabolism between platelets and PMN have also been reported. In particular, activated PMN can transform 12-HETE produced by activated platelets into 5S,12S di-HETE12J3 or 12,20 di-I-IETE from resting neutrophils.5J4J5 On the other hand, platelets are able to transform LT& derived from neutrophils into LTC416J7 or lipoXins.6J6J8
To the best of our knowledge, this is the first description of a platelet-PMN transcellular interaction in which platelets use AA released from fMLP-activated PMN to synthesize M2. In this experimental system, the activation of PMN not only results in activation of platelets "via" released cathepsin G, but also makes available AA to contiguous platelets, resulting in increased T x B 2 production.
Our results suggest a novel mechanism by which PMN might activate platelet function that could be relevant for thrombotic and inflammatory processes.
